Development of RNA Base Editing Technologies for Precision Medicines with Axiomer® and Trident® presented at TIDES USA 2022 by Gerard Platenburg - ProQR Therapeutics.
… its clinical stage pipeline programs and the Axiomer ® RNA editing platform. ProQR leadership will highlight key … design and assumptions. The QR-421a, QR-1123, QR-504a, and RNA editing platform technologies will also be featured. …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p
… highlighting the Company’s proprietary Axiomer ® RNA editing technology platform at upcoming scientific and … 15-16, 2023, in Basel, Switzerland; and the bi-annual RNA Editing Gordon Research Conference (GRC), March 19-24, …
